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Background. Alterations in TGF-β signaling are common in head and neck cancer (HNSCC). Mutations in TGF-β type II receptor
(TβR-II) occur frequently in HNSCC while TGF-β type I receptor (TβR-I) mutations are rare, suggesting that other molecular
alterations in the TGF-β pathway are likely. To identify abnormalities in TβR-I expression we analyzed 50 HNSCCs and correlated
the results with clinical-pathologic features. Methods. Hypermethylation of TβR-I was evaluated via methylation-speciﬁc PCR
(MSP) and restriction enzyme-mediated PCR (MSRE). Mutations in exons 1 and 7, mRNA and protein expression were analyzed
by direct sequencing, semiquantitative RT—PCR and immunohistochemistry, respectively. Results. TβR-I expression was lost in
83% HNSCCs and was linked to DNA hypermethylation of the CpG-rich promoter region in 62% of the tumors. The variants
9A/6A and Int7G24A were found in two patients. Conclusions. This study shows that suppression of TβR-I expression in HNSCC
is associated with DNA hypermethylation.
Copyright © 2009 Teresita Mu˜ noz-Antonia et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
Over 90 percent of head and neck cancers are squamous cell
carcinomas (HNSCCs) that arise from the mucosal lining of
the upper aerodigestive tract [1]. HNSCC is the ﬁfth most
common malignancy worldwide, with more than 500000
new cases diagnosed each year. It is estimated that these
tumors accounted for 45700 new cases and 11210 deaths in
2007 in the United States [2].
Patients often present with advanced stage disease and,
despite combined therapy, the 5-year survival rate of
approximately 50% has improved only marginally in recent
years. Tumors are typically staged by combining clinical
and pathological parameters of the primary tumor and its
metastases [3]. There are no reliable markers of early detec-
tion and prognosis, and the overall genetic and molecular
basis of HNSCC remains ill-deﬁned. The major risk factor
is epithelial exposure to tobacco and alcohol but, more
recently, human papillomavirus (HPV), an etiological agent
in cervical cancer, has been linked to HNSCC, especially in
the oropharynx [4, 5].
HNSCCsarefrequentlyresistanttothegrowthinhibition
mediated by transforming growth factor-β (TGF-β). In the
majority of cases, defects in the TGF-β type II receptor
(TβR-II) have been shown to play an important role in this
resistance. In a subset of tumors, however, the mechanism
responsible is not yet fully understood [6, 7].
The TGF-β superfamily is a set of multifunctional
cytokines that regulate numerous cellular functions includ-
ingproliferation,diﬀerentiation,organdevelopment,wound
healing, and immunity [8]. TGF-β eﬀects are mediated
by a membrane-bound serine/threonine kinase receptor
complex, consisting of type I and type II receptors [8, 9]a n d
theirdownstreamsignaltransducers,theSmadproteins[10].
Tumor cells escape TGF-β-mediated growth regulation via
the loss of one or more functional TGF-β receptors and/or2 International Journal of Otolaryngology
Smad proteins [10]. Since these abnormalities can result in
unregulated cell growth, various components of the TGF-
β signaling pathway are considered tumor suppressor genes
[9].
Genetic alterations and alterations of epigenetic infor-
mation are associated with malignant transformation and
progression in most cancers [11]. Modiﬁcation of DNA
methylation patterns and chromatin remodeling contribute
to epigenetic alterations of gene expression [11]. It has been
suggested that methylation silencing is as important as loss
of heterogeneity or mutations in cancer development [11]
and that each tumor appears to have a characteristic proﬁle
of methylated genes [12]. Mutations in TβR-II have been
frequently found in colon [13]a n dg a s t r i c[ 14]c a n c e r sb u t
a r el e s sf r e q u e n ti nH N S C C s[ 15, 16] and cancers of prostate
[17] and breast [18]. Mutations in TβR-I are less frequent
a n dh a v eb e e nr e p o r t e di nl y m p h o m a[ 19] and in ovarian
[20, 21] and pancreatic [22] cancers. A germline mutation,
Int7G24A, associated with susceptibility to cancer, has been
detected in carcinomas of the lung [23], kidney and bladder
[24],andbreast[25].Onestudyfoundnosomaticmutations
intheTβR-I genein30primaryHNSCCs[26]whileanother
found them in 4 of 21 metastatic HNSCCs [27]. Inactivating
mutations of the Smad2 gene have been detected in a
small group of human colorectal, lung, hepatocellular, and
cervical cancers [28]. Moreover, Smad4/DPC4 is inactivated
by somatic mutations in pancreatic, colonic, and pulmonary
carcinomas [29]. While methylation of the TβR-II promoter
region has been reported in esophageal [30] and nonsmall
cell pulmonary carcinomas [31], aberrant methylation of
TβR-I has been reported both in gastric cancer cell lines and
in primary gastric adenocarcinomas [32, 33].
Recently, we reported that Smad4 expression is signif-
icantly reduced in HPV16-positive compared to HPV16-
negative HNSCCs [34]. In the same study, we detected a
signiﬁcant reduction in the expression of TβR-I inm o s to f
the HNSCCs tested. In order to understand the molecular
mechanisms underlying this decrease in TβR-I expression in
HNSCCs, we investigated the possible presence of mutations
and aberrant methylation of the TβR-I gene promoter.
2.MaterialsandMethods
2.1. Patient Population. Fifty Puerto Rican patients who had
undergone surgery for HNSCC were included in this study.
Institutional Review Board approvals were obtained from
both the University of Puerto Rico Medical Sciences Campus
and the Moﬃtt Cancer Center. Complete sociodemographic
information was obtained for all patients (Table 1). There
were 42 males (84%) and 8 females (16%) ranging in
age from 38 to 84 years with a mean of 61.5 years.
Clinicopathological data collected included stage, tumor site,
degree of tumor diﬀerentiation, treatment method, date and
site of tumor recurrence and date and cause of death.
2.2. Immunohistochemistry of TGF-β Receptors. Immunohis-
tochemistry (IHC) protocols have been previously published
[34]. Tissue sections, 4μm in thickness, were deparaﬃnized,
rehydrated, incubated with 0.3% peroxide, washed in water
and subjected to antigen retrieval. Blocking serum was
applied and the slides blotted. Sections were then incubated
overnight,at4◦Cinahumidiﬁedatmosphere,withaprimary
anti TβR-I antibody (Santa Cruz Biotechnology, Santa Cruz,
Calif, USA) at a 1 : 100 dilution. Sections were then rinsed
with PBS and incubated with the secondary antibody for
30 minutes at room temperature. Detection was performed
using the Vectastain ABC kit, rabbit IgG, Elite series (Vector
Laboratories, Burlingame, Calif, USA). Antibody binding
was visualized using 3,3 -diaminobenzidine. Sections were
counterstained with hematoxylin. On each run, tissue sec-
tions, known to express the protein, were used as positive
controls and negative controls were incubated with PBS
instead of the primary antibody. Expression of TβR-I was
evaluatedinthetumorandinadjacentnonneoplasticepithe-
lium. Quantitation was performed, following the method
recommended by the College of American Pathologists,
as follows: 0 = no expression; 1+ = <25%cells; 2+ =
26–50% cells; 3+ = >50% cells.
2.3. Genomic DNA and RNA Isolation. Fresh-frozen tissue
samples were macrodissected to obtain a 90–95% purity of
nonnecrotic tumor and noninvolved adjacent nonneoplastic
epithelium.GenomicDNAwasisolatedfromboththetumor
and adjacent nonneoplastic tissue using the DNA Isolating
Kit for Cells and Tissues (Roche Applied Science, Hague
Road, Ind, USA). DNA from peripheral blood lymphocytes
was isolated using the QIAmp Blood DNA Maxi Kit from
Qiagen Inc. (Valencia, Calif, USA). For semiquantitative RT-
PCR analysis, total RNA was isolated from frozen tumor
tissue, using the RNeasy Midi Kit (Qiagen) and following
manufacturer’s speciﬁcations.
2.4. TβR-I Methylation Status. The methylation status of
the promoter region of TβR-I was assessed by restriction
enzyme-mediated PCR (MSRE) and methylation-speciﬁc
PCR (MSP). Genomic DNA, isolated from peripheral blood
lymphocytes (PBL), served as normal control. The DNA
from both tumor and nonneoplastic epithelium (150–
200ng) was digested for 6 hours with BstUI (New England
Biolabs, Ipswich, Mass, USA) according to conditions speci-
ﬁed by the manufacturer. PCR ampliﬁcation of unmodiﬁed
DNA and restriction digests were performed in a total vol-
ume of 25μL containing 1U FastStart Taq DNA polymerase
using the PCR buﬀer supplied by the manufacturer (Roche
Applied Science, Indianapolis, Ind, USA) with the addition
of GC-RICH Resolution Solution as recommended (200μM
dNTP, 200ng of DNA template, 2mM MgCl2, and 0.4μMo f
each primer). The sequences of sense and antisense primers
have been reported previously [32]. Reactions were hot-
started at 95
◦C for 5 minutes. This was followed by 35 cycles
of 30 seconds at 95
◦C, 90 seconds at 55
◦C, and 90 seconds at
72
◦C.Ampliﬁcationproductswereseparatedina2%agarose
gel, stained with ethidium bromide, and documented using
the Gel Doc 1000 System with Molecular Analysis Software
(BioRad, Hercules, Calif, USA). Ampliﬁcation products were
detected when digestion of the tumor genomic DNA withInternational Journal of Otolaryngology 3
Table 1: Relationship between clinicopathological features of HNSCC patients and TβR-I gene promoter aberrant methylation.
No. Patients (%) Methylation (%) P
All patients 50 (100) 31( 62)
Male 42 ( 84) 27 (64)
Female 8 (16) 4 (50) 0.450
Site
Oral Cavity 22 (44) 13 (59)
Oropharynx 5 (10) 4 (80)
Hypopharynx 6 (12) 3 (50)
Larynx 17 (34) 11 (65) 0.756
Tumor diﬀerentiation
Well diﬀerentiated 13 (26) 10 (76)
Mod. diﬀerentiated 30 (60) 19 (63)
Poorly diﬀerentiated 5 (19) 4 (80) 0.649
n.a. 2 ( 4)
Disease stage
I 4 ( 8) 3 (75)
II 7 (14) 5 (71)
III 13 (26) 8 (62)
IV 26 (52) 15 (57) 0.917
Median age (range), y 61.54 (38–84)
Abbreviation: na Not available.
methylation-sensitive restriction endonuclease BstUI was
inhibited by the presence of the methylated CpG motifs.
Since incomplete digestion of genomic DNA with BstU1
could result in false positives, the procedure was per-
formed twice to ensure full digestion and reproducibility of
results.
Aberrant methylation was independently tested by
methylation-speciﬁc PCR (MSP). This method relies on the
conversion of unmethylated cytosine to uracil by sodium
bisulﬁte. Genomic DNA (1μg) was modiﬁed by bisulﬁte
treatment using the CpGenome DNA modiﬁcation kit fol-
lowing manufacturer’s instructions (Intergen Co., Purchase,
NY, USA). The primer sets used anneal speciﬁcally to the
methylated bisulﬁte-modiﬁed DNA and are described else-
where [32]. PCR was performed using 5μLo fe a c hb i s u l ﬁ t e -
modiﬁed DNA as template in a 25μL volume containing
1U FastStart Taq DNA polymerase in the buﬀer supplied by
themanufacturer(RocheAppliedScience),withtheaddition
of GC-RICH Resolution Solution as recommended (200μM
dNTP, and 0.4μMo fe a c hp r i m e r ,2 m MM g C l 2 and 5%
DMSO). The reaction mixture was incubated at 95
◦Cf o r
5minutes and then subjected to 35 cycles of ampliﬁcation
consisting of 1 minute at 95
◦C, 90 seconds at 55
◦C, and 90
seconds at 72
◦C and a ﬁnal extension of 7 minutes at 72
◦C.
The ampliﬁed fragments were subjected to electrophoresis
in a 3% agarose gel, stained with ethidium bromide and
documented using the Gel Doc 1000 System with Molecular
Analysis Software (BioRad).
2.5. TβR-I RNA expression. For semiquantitative RT-
PCR analysis, total RNA was isolated from macrodiss-
ected (enriched) fresh frozen tumor tissue, suitable for
mRNA analysis, using the RNeasy Midi Kit (Qiagen,
Valencia, Calif, USA) following manufacturer’s specif-
ications. Complimentary DNA (cDNA) was prepared
from each sample using M-MLV reverse transcriptase
(Gibco BRL, Life Technologies, Carlsbad, Calif, USA).
Primers for the TβR-I gene were designed using
the Primer 3 program at http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3 www.cgi and tested for uniqueness
in BLAST. cDNA was ampliﬁed with the TβR-I gene
primers 5 -GGTCTTGCCCATCTTCACAT-3  (sense) and
5 -TTGCTCCAAACCACAGAGTG-3  (antisense). Primer
ampliﬁcation was performed by adding 2μL of each cDNA
sample to a ﬁnal reaction mixture of 25μL containing 1U
FastStart Taq DNA polymerase in the buﬀer supplied by the
manufacturer (Roche Applied Science), with the addition of
GC-RICH Resolution Solution as recommended (200μM
dNTP, 0.4μMo fe a c hp r i m e r ,a n d2m MM g C l 2). PCR cycle
conditions were experimentally determined in order to
maintain a linear stage. The PCR conditions were: 95
◦Cf o r
5 minutes followed by 30cycles of ampliﬁcation consisting
of 1 minute at 95
◦C, 45 seconds at 59
◦C, 1 minute at 72
◦C
and a ﬁnal extension of 7 minutes at 72
◦C. ACTB was used
to normalize the amount of mRNA present in each sample.
Control reactions without DNA were included in each assay.
The PCR products were separated in a 2.5% agarose gel,
stained with ethidium bromide, and documented with the
Gel Doc 1000 System and Molecular Analysis Software
(BioRad). Measurements were performed twice to ensure
reproducibility of results. The levels of gene transcripts were
quantiﬁed as the ratio of intensity of target signal to the
intensity of ACTB signal, using the Bio-Rad’s Quantity One
software package.4 International Journal of Otolaryngology
2.6. TβR-I Genotyping. Genomic DNA (gDNA) was
ampliﬁed using primers speciﬁc for exons 1 and 7.
Exon 1 (>70% GC rich) was ampliﬁed using the
primers 5 -GAGGCGAGGTTTGCTGGGTGAGGCA-3 ;
5 -CATGTTTGAGAAAGAGCAGGAGCGAG-3 , and the
Advantage-GC Genomic PCR Kit from Clonetech labora-
tories (Mountain View, Calif, USA). Exon 7 was ampliﬁed
using the primers: 5 -AAAGGAGGTTCATCCAAATA-3 ;
5 CAACTTCTGATGCTCATGACAAA-3 .P C Rp r o d u c t s
were generated in a volume of 50μL containing 500ng of
genomic DNA, 10X PCR Buﬀer (100mM Tris-HCl [pH
8.3], 500mM KCl, 15mM MgCl2, 0.1% Gelatin), 0.25mM
each of dNTP, 100ng of each primer, 0.056μM TaqStart
Antibody (Clontech Laboratories, Palo Alto, Calif, USA) and
2.5 Units of Taq (Gibco/BRL, Gaithersburg, Md, USA). The
PCR parameters were as follows: initial denaturing at 60
◦C
for 3 minutes and 94
◦C for 5 minutes, followed by 30cycles
of 94
◦C, 1 minute; 55
◦C, 1 minute; 72
◦C, 1 minute, followed
by one extension cycle of 94
◦C, 1 minute; 55
◦C, 2 minutes;
72
◦C, 5 minutes. The PCR fragments were puriﬁed using the
Freeze and Squeeze DNA Puriﬁcation Kit (BioRad).
2.7.DNASequencing. DNAsequencingwasperformedatthe
University of Pennsylvania DNA Sequencing Facility on an
ABI (Applied Biosystems) sequencer 3730XL with BigDye
Taq FS Terminator V 3.1.
2.8. Statistical Analysis. The Fisher’s Exact test was used for
correlation analysis. A P<. 05 was considered statistically
signiﬁcant.
3. Results
In order to investigate potential mechanisms of inactiva-
tion of the TGF-β signaling pathway in squamous cell
carcinomas of the head and neck (HNSCC), we examined
the methylation and mutation status of the TβR-Igene in
HNSCC samples from 50 patients. Of these, 42 HNSCCs
(84%) were analyzed, by IHC, in archived formalin-ﬁxed,
paraﬃn-embedded tissue sections. Twenty-ﬁve (50%) fresh
frozen samples, suitable for mRNA analysis, were tested
for RNA expression by semiquantitative RT-PCR. The
frequency of TβR-I promoter aberrant methylation was
detected using restriction enzyme-mediated (BstUI) PCR
and methylation speciﬁc PCR (MSP). The results of all
threemethods,immunohistochemistry,geneexpression,and
methylation analyses, are summarized, in the context of
clinical-pathological features, in Tables 1 and 2.W eo b s e rv e d
no statistically signiﬁcant associations between the results
obtained by any of the three methods and patient’s sex,
tumor anatomical location, degree of diﬀerentiation, or
tumorstage(Table 1).Representativeresultsofthemolecular
analysis are shown in Figures 1(a)–1(c).T h ep r e s e n c eo f
ampliﬁed products in BstUI-digested DNA (lanes with the
+ sign) indicates that the TβR-I promoter is methylated in
the tumor (Figure 1(a); samples 6, 8, 30, 37, and 46).L a c k
of TβR-I PCR product in normal lymphocytes, treated with
methylation-sensitiveBstUI,isindicativeofanunmethylated
HN M 6 8 30 37 46
++ + + ++ -- - - --
(MSRE)
(a)
8 91 0 12 13 30 32 34 35 39 43 44 46
(MSP)
(b)
M  32 39
(RT-PCR)
28 16 38 23
rrr r r r
19
cccr cccc
(c)
Figure 1: Analysis of TβR-I promoter status and gene function
in HNSCCs. (a) Representative examples of restriction enzyme-
mediated PCR (MSRE) experiments. Analyses were performed for
each tumor in the presence (+) and in the absence (−)o fBstUI
as described in Materials and Methods. Presence of PCR products
in (+) lanes indicates methylated DNA. Methylation of TβR-I was
detected for carcinomas 6, 8, 30, 37, and 46. A positive control
of peripheral blood lymphocytes DNA (H) shows unmethylated
DNA. A negative (N) control without DNA was used in each assay.
M: molecular size marker 100bp. (b) Methylation-speciﬁc PCR for
bisulﬁte-modiﬁed DNA that was ampliﬁed with primers speciﬁc
for methylated alleles, as described in Materials and Methods.
The presence of PCR products (Lanes 1 to 9 and 11 to 12) is
indicative of a methylated TβR-I gene promoter. Lane 10 (HNSCC
no. 39) shows an unmethylated DNA. (c) Semiquantitative RT-
PCR analysis of TβR-I gene expression in representative samples of
HNSCCs. Expression of ACTB gene was used as a control for RNA
integrity. Relative mRNA level was normalized based on that of β-
actin (153 bp). The length of the TβR-I PCR product is 186bp.
The agarose gel image was taken from a 30-cycle PCR. TβR-I (a)
and ACTB (b) PCR products were visualized after electrophoresis
through 2.5% agarose. HNSCC samples 28, 16, 38, 19, 23, 32 have
lost or show reduced mRNA expression. HNSCC sample 39 had
preserved mRNA expression. M: molecular size marker 50bp.
promoter cleaved by the restriction enzyme (Figure 1(a),
lane H). In our series, 31 samples (62%) showed aberrant
methylation of the TβR-I gene promoter. Both methods
detected hypermethylation in 30 HNSCCs and only by
MSP in one additional sample [Figure 1(b), no. 43]. MSP
is the most sensitive of the two methods and can detect
one copy of methylated DNA in 1000 (0.1%) unmethylated
copies of genomic DNA [35]. The frequency of TβR-I
hypermethylation was highest in the oropharynx (80%) and
lowest in the hypopharynx (50%).
To establish if there was a relationship between methyla-
tion and expression of mRNA or protein, we simultaneously
analyzed the HNSCCs by RT-PCR (Figure 1(c))a n dI H C
(Figure 2). Of the 42 tumors tested by IHC, 35 (83%) com-
pletely lost protein expression, 5 (12%) showed a reduction
of expression compared with adjacent nonneoplastic tissue
and in two cases (5%) the tumor showed no reduction
of protein expression (Table 2; Figure 2). Of the 7 IHC-
positive cases, 3 (49%) showed abnormal methylation and
4 (57%) did not (Table 3). On the other hand, of the 35
IHC-negative tumors, 24 (69%) were aberrantly methylated
and 11 (31%) were not. Methylation was in agreement withInternational Journal of Otolaryngology 5
(a) (b)
Figure 2: Immunohistochemistry of TβR-I p r o t e i ni nH N S C C s
(200X). (a) Immunohistochemical detection of TβR-I protein
(brown signal in nonneoplastic epithelium adjacent to HNSCC).
(b) Lack of TβR-I protein staining in the HNSCC.
IHC in 64% of the cases but no strong correlation (P =
.389) was observed (Table 3). This lack of agreement has
been reported in previous studies [36] and thought to be
the result of subjective interpretation of IHC results with
no uniformly accepted threshold for positivity. With regard
to gene expression, of the total of 21 tumors tested, 18
(90%) showed complete loss or downregulation of mRNA
expression and 3 (14%) were fully expressed. Of the 18 with
altered mRNA expression 17 (94%) lost protein expression
and 1 (6%) did not (Table 3). This suggests that decreased
protein expression was likely due to downregulation of gene
expression. In these 21 cases, an agreement with IHC results
was observed on 90% of the cases, and this correlation was
statistically signiﬁcant (P = .042).
Also, a strong correlation was found between methy-
lation status and TβR-I mRNA expression detected by
comparative RT-PCR analysis using the ACTB transcript as
an internal standard (Figure 1(c)). A 186 bp fragment of the
TβR-I gene transcript was generated and compared with a
153 bp transcript of the ACTB gene. Complete expression of
TβR-I transcripts was observed in four samples (no. 25, 34,
36, and 39) in concordance with lack of hypermethylation
of the gene promoters (Figure 3, lanes 9, 17, 19, and 20).
TβR-I mRNA expression was reduced or absent in 21 of the
25 tumors tested (84%) and, in these samples, a concordance
(P = .003) between TβR-I gene promoter hypermethylation
and TβR-I gene expression was observed (Table 4). The loss
ofmRNAexpressioninHNSCCsno.33,39,and40(Figure 3,
lanes 16, 22, 23), which lack TβR-I aberrant methylation,
could be explained by other mechanisms such as epigenetic
histone alterations [37].
Of the 25 tumors in which aberrant methylation and
gene expression were simultaneously studied (Table 4), 18
(72%) are methylated and 7 (28%) are not methylated. Also,
of the 25 tumors, 4 (16%) show normal gene expression,
12 (48%) had partial loss of gene expression, and 9 (36%)
show complete loss of gene expression. Of the 18 that are
methylated 10 (55%) show downregulation of the gene and 8
(44%) have completely lost gene expression. In the 4 tumors
in which the promoter is not methylated the gene is fully
expressed indicating that lack of methylation correlates with
normal gene expression. Of the 3 remaining tumors in which
the promoter was not methylated, 1 (33%) showed no gene
expression.
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Figure 3: Schematic depiction of TβR-I expression by semiquan-
titative RT-PCR, and hypermethylation by MSP. Tumors with
methylated (red bars) and nonmethylated (blue bars) genes are
depicted in association with TβR-I levels of expression. Columns
(white, grey, and dark grey) correspond to relative expression levels
(arbitraryunits)ofTβR-I determinedbysemiquantitativeRT-PCR.
Methylated genes are associated with lower expression levels of the
TβR-I gene.
Later, we found that in this case (no 33) the gene has a
mutation in exon 1. Another tumor not expressing the gene
(no 40) showed a mutation in exon 7. Finally, in another
tumor (no 41) the promoter is not methylated and there are
no detectable mutations but the gene is downregulated and
protein expression is lost.
Mutations in the TβR-I gene have been identiﬁed in
ovarian, pancreatic, lung, and breast carcinomas [20–25].
Previous studies, however, showed that mutations within
the coding sequence of TβR-I are rare in HNSCC [26]. We
examined twenty-ﬁve HNSCC for mutations in the TβR-I
gene by PCR and direct sequencing of the PCR products. Of
the twenty-ﬁve samples, 13 (nos. 10, 11, 12, 22, 24, 26, 27,
29, 31, 33, 38, 40, and 50) belonged to this cohort of HNSCC
patients and the other 12 samples (data not shown) were
from HNSCC patients treated at Moﬃtt Cancer Center.
We conﬁrmed that mutations of the TβR-I gene are,
indeed, rare. Sequencing revealed polymorphic sequence
c h a n g e si no n l yt w ot u m o r s .B o t ht u m o r sa r ef r o mo u r
series (no. 33 and no. 40). An intronic G/A variant, 24 bp
downstream of the exon/intron 7 boundary, was detected in
sample no. 33. This polymorphism has been associated with
various cancer types [20–25]. In addition, a nine-base pair
deletion in exon-1, [del(GGC)3] , was identiﬁed in sample
no. 40 in both the tumor and in nontumor genomic DNA.
Thisdeletioncouldrepresentthegermlinedeletionidentiﬁed
previously by Pasche et al. [38].
4. Discussion
Epigenetic mechanisms (DNA methylation, histone modiﬁ-
cations,andchromatinremodeling)arealteredincancerand
playacentralroleintheinitiationandprogressionofthedis-
ease [11, 12, 37]. The pattern of aberrant hypermethylation
is speciﬁc for each tumor type [12]. Our results implicate,
for the ﬁrst time, the TβR-Igene as a target for inactivation6 International Journal of Otolaryngology
Table 2: Correlation between, tumor characteristics, protein and mRNA expression, and promoter methylation. Grading and tumor, lymph
node, metastasis, and staging (TNM) are according to the 2002 UICC classiﬁcation.
Tumor Age Site Diﬀerentiation Stage Protein expression  Expression TβR-I Methylation TβR-I expression
Normal Carcinoma
1 82 HP MD IV 2+ 1+ Decreased NM
2 67 L MD IV 2+ 0 Lost NM
3 57 L MD IV 1+ 0 Lost M
4 64 L PD III 1+ 0 Lost NM
5 75 L MD II 1+ 0 Lost M
67 9 O CM D I I I 1 + 0 L o s t N M
7 56 OP MD IV 2+ 1+ Decreased NM
85 3 O PM D I V 1 + 0 L o s t M
97 1 O CW D I I I 1 + 0 L o s t M
10 84 OP MD III 2+ 0 Lost M 2
11 73 L MD IV 1+ 0 Lost M 3
12 67 OC WD III 2+ 0 Lost M 3
13 38 L MD I 1+ 0 Lost M 2
14 48 HP MD 1V na na na NM
15 62 OP MD II 2+ 1+ Decreased M
16 58 L MD III 3+ 0 Lost M 2
17 66 OC PD III 1+ 0 Lost NM
18 50 L SCC IV 2+ 0 Lost NM
19 55 OC MD IV na na na M 3
20 58 OC WD IV 2+ 0 Lost NM
21 46 OC WD III 3+ 0 Lost M
22 66 OC MD I 1+ 0 Lost M 3
23 70 L WD IV 2+ 0 Lost M 2
24 51 OP WD IV 1+ 0 Lost M
25 74 HP MD IV na na na NM 1
26 56 OC MD I 3+ 0 Lost M 2
27 66 HP PD III 1+ 0 Lost M 2
28 68 OC MD II 2+ 0 Lost M 2
29 81 OC MD IV 3+ 0 Lost M 3
30 55 L MD II 2+ 0 Lost M
31 44 L MD IV 1+ 0 Lost M 2
32 55 OC MD IV 1+ 0 Lost M 3
33 84 OC SCC I na na na NM 3
34 56 OC WD II 1+ 1+ Unchanged NM 1
35 74 HP PD IV 1+ 0 Lost M 2
36 60 OC PD II 3+ 0 Lost NM 1
37 60 L WD IV 3+ 0 Lost M
38 56 L WD II na na na M 3
39 56 L MD IV 3+ 1+ Decreased NM 1
40 48 L MD III 2+ 0 Lost NM 2
41 62 OC MD IV 1+ 0 Lost NM 2
42 65 L WD IV 3+ 0 Lost NM
43 47 OC MD III 3+ 1+ Decreased M 3
44 75 L MD III na na na M
45 51 OC WD IV 3+ 3+ Unchanged M
46 49 OC WD IV na na na M
47 70 OC MD IV na na na NM
48 47 OC MD III 1+ 0 Lost NM
49 50 HP MD IV 1+ 0 Lost M 2
50 72 OC WD IV 2+ 0 Lost M
OC = Oral cavity, OP = Oropharynx, HP = Hypopharynx, LA = Larynx, na = Not available. 1 = Fully expressed; 2 = Down-regulated; 3 = Not expressed. WD
= Well diﬀerentiated, MD = Moderately diﬀerentiated, PD = Poorly diﬀerentiated, SCC = Squamous cell carcinomaInternational Journal of Otolaryngology 7
Table 3: Relationship between TβR-I gene promoter aberrant methylation and TβR-I protein expression.
Methylation Gene expression
Protein expression (IHC) + − Complete Partial None
Positive 3 4 2 0 1
Negative 24 11 1 12 5
Total 27 (64%) 15 (36%) 3 (14%) 12 (57%) 6 (29%)
P value 0.389 0.042
Table 4: Relationship between TβR-I gene promoter aberrant methylation and gene expression.
Gene expression Total (%)
Complete Partial None
Methylated 0 10 8 18 (72%)
Not Methylated 4 2 1 7 (28%)
Total (%) 4 (16%) 12 (48%) 9 (36%) 25 (100%)
by aberrant methylation in head and neck squamous cell
carcinoma.
Disruption of the TGF-β signaling transduction pathway
has been shown in a signiﬁcant subset of human cancers.
Key steps are the formation of a heterodimeric complex
between receptors type II and type I, phosphorylation of
type I receptor and activation of the downstream targets.
The fact that aberrant methylation of TβR-I is likely to be
an important step in cancer progression is supported by a
similar observation in gastric cancer cell lines and in primary
gastric adenocarcinomas [32, 33]. Our studies conﬁrm
previous studies by Pinto et al. [33] who demonstrated that
aberrant methylation of the TβR-I gene, in gastric tumors, is
associated with loss of gene transcription. Gene inactivation
resulted on loss of RNA and protein expression (Tables 3 and
4). Our study also reveals a signiﬁcant association between
promoter hypermethylation and loss of gene expression.
However a strong association with reduction or loss of
protein expression could not be established. Loss of protein
expression, measured by IHC, appears not to be a good
predictorofDNAmethylation-dependentgenesilencing[36,
39] suggesting that diﬀerent gene silencing mechanisms such
as histone modiﬁcations are likely to occur [40].
Recently, inactivation of TβR-II in lung cancer cell
lines has been associated with alterations in the chromatin
structure of the promoter region, most probably by his-
tone deacetylation [37]. DNA methylation at the TβR-II
promoter of exon 1 was also detected in a group of cells
suggesting that aberrant methylation also played a role
in the loss of TβR-II expression. It would be of interest
to determine whether, in these tumors, alterations of the
chromatin structure contribute to the inactivation of TβR-I.
On the other hand, the aberrant methylation, detected in
one sample, only by MSP, can be explained by the inherent
sensitivity of the method which can detect methylated alleles
in 0.1% of a total DNA sample [35].
Mutations of TβR-I have been detected in metastatic
HNSCCs [27]. In our series, we found two tumors with
mutations in the coding region of TβR-I. In HNSCC no. 40,
an Int7G24A was detected in exon 7. The Int7G24A variant
in TβR-I has been detected more frequently in patients
with carcinomas of kidney and bladder than in normal age-
matched controls [24]. In a study of HNSCCs, 17% of the
carcinomas were heterozygous for Int7G24A [26]. This is
consistent with our data, since we detected this alteration
in only one of the tumors examined. Also, we detected a
common polymorphism of TβR-I, TGFβR1
∗6A , consisting
of a deletion of 3 alanines within a 9-alanine repeat at the
3  end of the exon 1 coding sequence [38, 41]. Previously,
Pasche et al. [38] showed that TGFβR1
∗6A is somatically
altered in cancer and functions as a tumor susceptibility
allele. More recently, Pasche et al. [41] reported that the
TGFβR1
∗6A variant is rarely found (1.8%) in primary
HNSCC. This alteration, found in one of our samples (no.
33), has been described in many cancer types. A recent meta-
analysis of several large cohorts, which included a total of
13113 individuals [42], supports the hypothesis, proposed
byPasche[38],thatTGFβR1
∗6Aisassociatedwithincreased
cancer risk. More recently, Bian et al. demonstrated that
somatic acquisition is a critical event in the early stages of
cancer development associated with ﬁeld cancerization [43].
Our ﬁndings show that TβR-I is a primary target for
aberrant methylation. This can explain previous obser-
vations of TβR-I loss of expression. Studies by Mi et
al. [44] showed that TGF-β resistance, at late stages of
HPV16-mediated transformation of human keratinocytes,
is the result of a loss of expression of TβR-I. This sig-
niﬁcant decrease in mRNA levels can be explained by
hypermethylation of the TβR-I promoter region. Similarly,
Marsit et al. [45] found that promoter methylation in
the secreted frizzled-related protein 4 (SFRP4)g e n ew a s
independently associated with the presence of HPV16 viral
DNA in HNSCC. SFRPs are antagonists of Wnt signaling
thatinhibitWntreceptorbindinganddownregulatepathway
signaling in development. SFRP4 has been found frequently
methylated in colorectal cancer and in chronic lymphocytic
leukemia [46, 47]. We have previously shown a high fre-
quency of HPV16 infection in Puerto Ricans with HNSCCs8 International Journal of Otolaryngology
[4]. Studies are under way to ascertain if infection with
HPV16 facilitates hypermethylation of genes associated with
cancer in HNSCCs.
Analysis of the association between TβR-I aberrant
methylation and prognostic factors (Table 1)s u c ha sa g e ,
gender, stage, and tumor site showed no statistically sig-
niﬁcant correlations. However, TβR-I aberrant methylation
was shown in early (I and II) and advanced (III and IV)
tumor stages suggesting that epigenetic disruption of TGF-
β signaling by aberrant methylation might contribute to the
progression of HNSCCs.
5. Conclusion
Our ﬁndings indicate that epigenetic silencing is the main
mechanism of inactivation of TβR-I in HNSCCs. Gene
methylation occurs frequently in human cancers and has
been demonstrated early in tumorigenesis. Several studies
have shown that promoter methylation of cancer genes is
speciﬁc to preneoplastic and neoplastic cells [48]. DNA
methylation may be present before the cancer is detected by
conventional methods and, thus, can simultaneously provide
diagnosticandprognosticinformation.PCR-baseddetection
of hypermethylated genes both in tissue and in body ﬂuids
such as urine or blood can be useful in cancer diagnosis.
For a biomarker to be useful in the detection of early
cancer, however, it has to discriminate between neoplastic
and nonneoplastic cells.
More comprehensive studies, including tumors and
matched controls, are needed to address the sensitivity,
speciﬁcity, and predictive value of TβR-I methylation-based
cancer detection. Nevertheless, TβR-I hypermethylation has
already shown to have a signiﬁcant degree of speciﬁcity in
gastric cancer, and it appears that the same is very likely
for head and neck cancer. Diﬀerent frequencies of a variety
of methylated cancer genes are reported in diﬀerent cancer
types suggesting that accurate diagnosis of a speciﬁc cancer
type may require the detection of a panel of hypermethylated
genes present at high frequency in the tumor cells. Further-
more, gene methylation can potentially be evaluated in the
patients sera to detect early recurrences in those primary
tumors that display a given methylation pattern. Thus, in
addition to CDKN2A, TβR-I gene could be added to the list
of cancer genes that must be tested for methylation-based
detection of head and neck cancer.
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